Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data [0.03%]
银屑病治疗升级的影响因素分析：基于电子病历数据的研究
Jamie L W Rhoads,William N Malatestinic,Russel Burge et al.
Jamie L W Rhoads et al.
Background: Electronic health records (EHRs) offer the possibility of using data entry templates to simultaneously document routine clinical care and capture disease-specific measures as discrete data elements that can be...
Nailfold Capillaroscopy Findings in Patients With Psoriasis Vulgaris and Different Domains of Psoriatic Arthritis [0.03%]
寻常型银屑病及不同分型的银屑病关节炎患者甲皱微循环变化的研究
Amal M Elmesiry,Sobhia A Mahmoud,Maha S Mohamed et al.
Amal M Elmesiry et al.
Background: Psoriasis is a chronic autoimmune disease with longtime activity and multisystem affection. Nailfold capillaroscopy (NC) is a simple noninvasive microscopic tool useful for identification of nailfold microvasc...
Review of Integrative Medical Therapies for Psoriasis: The Microbiome, Probiotics, Diet, and Mindfulness [0.03%]
银屑病整合医学疗法的研究：微生物群系、益生菌、饮食和正念疗法
Mildred Min,Ajay S Dulai,Nabeel Ahmad et al.
Mildred Min et al.
Background: Psoriasis is a chronic inflammatory condition with cutaneous and systemic involvement. Although many efficacious treatment options are available, concerns regarding costs and duration of treatment have expande...
Analyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers [0.03%]
《安全步骤法案》的利弊分析——患者、医生和保险公司的视角
Divya M Shan,Jonathan D Greenzaid,Estay Greene et al.
Divya M Shan et al.
Pharmaceutical expenditures in the United States, particularly in dermatology, have grown rapidly, driven by expensive topical and biologic treatments. Insurers are employing cost-containing strategies such as step therapy, which mandates t...
Whole-Genome Shotgun Metagenomic Sequencing Reveals Shifts in the Skin Microbiome and Bacteriophages of Psoriasis: An Extended Analysis of Published Data [0.03%]
全基因组鸟枪法元基因组测序揭示了银屑病皮肤微生物群和噬菌体的变化：已发表数据的扩展分析
Yvonne Nong,Dana M Walsh,Jessica Maloh et al.
Yvonne Nong et al.
Background: Psoriasis is an immune-mediated cutaneous disease that may have shifts in the skin microbiome. Prior research on the skin microbiome in psoriasis has been limited to rRNA based approaches that lack resolution ...
Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study [0.03%]
丹麦生物制剂治疗银屑病患者的特征——一项基于队列的研究
Christopher Willy Schwarz,Lone Skov,Alexander Egeberg et al.
Christopher Willy Schwarz et al.
Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and respo...
Andrew Blauvelt
Andrew Blauvelt
Correlation between Carotid Artery Mean Intima-Media Thickness and brain Natriuretic Peptide in Patients with Psoriasis [0.03%]
银屑病患者颈动脉中膜厚度与脑钠肽的相关性研究
Nasim Niknezhad,Mohammad Shahidi-Dadras,Fateme Rajabi et al.
Nasim Niknezhad et al.
Background: Numerous studies have documented an association between psoriasis and subclinical atherosclerosis. Objective: We aimed to i...
Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies [0.03%]
商业保险公司对银屑病和银屑病关节炎专科药物的覆盖情况
Christine Learned,Sara Alsukait,Kristin R Fiumara et al.
Christine Learned et al.
Background: Specialty medications provide effective treatment with limited adverse effects to patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment ...
Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival [0.03%]
美国一家学术医学中心银屑病患者多种生物制剂使用相关的因素及生物制剂有效周期的回顾性研究
Edward Hadeler,Sugandh Kumar,Samuel Yeroushalmi et al.
Edward Hadeler et al.
Background: Despite their impressive efficacy in phase 3 trials, biologic agents for psoriasis (PsO) may lose efficacy over time. The factors associated with loss of efficacy have yet to be fully elucidated. ...